Search PubMed⌕ Search

Biomedical subjects

P Baird

Publications and source records attributed to P Baird.

27 records · Page 2Linked to original sources
PubMed1993

Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.

Loss of heterozygosity (LOH) in tumour cells is generally accepted as 'exposing' recessive cancer genes. The short arm of chromosome 11 shows consistent LOH in Wilms' tumours along its entire length. Occasionally, however, only the 11p13 and/or the 11p15 regions are involved. Deletions of the 11p13 region consistently predisposes to Wilms' tumorigenesis. We have analysed the recently cloned WT1 gene from the 11p13 region exon-by-exon in five tumours previously shown to have undergone LOH for the 11p13 region, using single strand conformation polymorphism analysis (SSCP) and PCR sequencing. Our analysis using SSCP failed to identify any band shifts in the WT1 gene from these tumours. In addition we also sequenced the zinc finger region of WT1, which is the part of the gene most frequently showing mutations. Only the normal sequence was found in all of these tumours. These results demonstrate that LOH in Wilms' tumours is not always related to mutations in the WT1 genes and argues strongly that another gene, probably in the 11p15 region, may be more important in Wilms' tumorigenesis.

Alleles↗
PubMed1991

Loss of heterozygosity for chromosome region 11p15 in Wilms' tumours is not related to HRAS gene transforming mutations.

Although a candidate Wilms' tumour gene--WT1--has been identified in chromosome region 11p13, there is strong evidence from loss of heterozygosity studies suggesting that a second relevant gene is present in region 11p15. The Harvey-Ras proto-oncogene also lies in this region. In other types of tumours mutations in RAS genes have been associated with the development and/or progression of a number of tumour types. We therefore analysed the sequence of the Ras oncogene for possible mutations in six Wilms' tumours showing loss of heterozygosity for chromosome region 11p15. No tumour analysed showed HRAS sequence mutations. We conclude that loss of heterozygosity at 11p15 does not implicate HRAS mutations in the molecular pathogenesis of Wilms' tumour.

Base Sequence↗
PubMed1978

Penetration into bone and tissues of clindamycin phosphate.

Clindamycin phosphate is an antibiotic which is effective against both Staphylococcus aureus and the anaerobic organisms. In thirteen patients, its concentration following joint replacement was measured by the agar diffusion method. In bone, the concentration was (mean +/- s.e. mean) 5.01 microgram/ml +/- 1.16, N=10; in capsule, 3.29 microgram/ml +/- 0.71, N=12; measured between 1.75 and 3.75 hr after intramuscular and intravenous injections, and in drainage fluid it amounted to 4.61 microgram/ml +/- 0.38, N=11 in 48 hr. Two patients developed diarrhoea which settled within a short period.

Aged↗